Anonymous ID: c4e5da April 16, 2021, 5:33 p.m. No.13442793   🗄️.is 🔗kun   >>2985 >>3010 >>3132 >>3338 >>3409

A study released today by Oxford University found the number of people who developed CVST blood clots after COVID vaccines was about the same for Pfizer, Moderna and AstraZeneca, MarketWatch reported. (J&J is not approved for use in the EU, where the study originated).

According to the study, 4 in 1 million people experienced CVST during the two weeks following vaccination with the Pfizer or Moderna vaccine, versus 5 in 1 million people for the AstraZeneca vaccine.

Although researchers found a significantly higher incidence of blood clots in people who were infected with COVID, the incidence of blood clots following vaccines was still much higher than the background incidence of 0.41, a strong signal that the vaccines pose this specific risk.

“These findings are consistent with what we know about how vaccine-induced spike proteins can on their own cause cell signaling through interactions with the ACE-2 receptors,” said Lyn Redwood, RN, MSN, president emerita of Children’s Health Defense. “When this happens, it can result in inflammation and a host of other potentially pathological events in the epithelial lining of the blood vessels which can then trigger pro-inflammatory cytokines capable of activating coagulation systems and down-regulating anticoagulant pathways resulting in clot formation.”

A study published February in the Journal of Hematology examined thrombocytopenia following Pfizer and Moderna vaccination in response to the death of a 56-year-old Florida physician — the first identified patient who died from a brain hemorrhage after receiving Pfizer’s vaccine.

Researchers examined 20 case reports of patients with immune thrombocytopenia (ITP) following vaccination, including 17 without pre‐existing thrombocytopenia using data from the CDC, FDA, U.S. Department of Health and Human Services, Vaccine Adverse Events Reporting System (VAERS), published reports, and communications with patients and treating providers.

After analyzing data researchers could not exclude the possibility that the Pfizer and Moderna vaccines had the potential to trigger ITP and recommended additional surveillance to determine the incidence of thrombocytopenia post vaccination.

“While the main concern associated with ITP is bleeding, it may come as a surprise that ITP is also associated with a 20% increased risk for blood clots,” Redwood said, pointing to a March 8 article by Dr. Robert Bird, director of haematology at Princess Alexandra Hospital in Brisbane, Australia.

 

https://childrenshealthdefense.org/defender/pfizer-moderna-vaccines-blood-clots/